Ion Channel Markers for DCIS Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating ductal carcinoma in situ (DCIS) lack effective tools to distinguish between low-risk and high-risk cases, leading to unnecessary aggressive treatment for many patients, as there are no robust prognostic factors to predict the likelihood of DCIS progressing to invasive ductal cancer.
Innovation Solution
The use of specific ion channels, such as TRPV4 and ATP1A1, localized at the plasma membrane of DCIS cells as diagnostic markers to predict the risk of invasive transition, allowing for personalized treatment approaches by identifying cells with a high likelihood of becoming invasive through methods like immunohistochemistry and flow cytometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aggressive treatment (surgery and radiation) is applied to all DCIS patients, then the likelihood of treating potential invasive cancers is improved, but unnecessary physical discomfort and anxiety are caused to patients with low-risk DCIS
Solution Approach 1:
The patent segments DCIS patients into high-risk and low-risk groups based on ion channel expression profiles. By dividing the homogeneous treatment approach into stratified groups, the patent enables targeted treatment where only high-risk patients receive aggressive therapy, thereby eliminating unnecessary side effects for low-risk patients while maintaining effective treatment for those who need it.
Solution Approach 2:
The patent introduces ion channel expression analysis as an intermediary diagnostic tool between DCIS diagnosis and treatment decision-making. This intermediary biomarker assessment provides objective criteria for risk stratification, allowing clinicians to make informed treatment decisions based on molecular characteristics rather than applying uniform aggressive treatment to all patients.
2Reliability
If uniform aggressive treatment is provided to all DCIS patients, then potential invasive cancers are addressed, but treatment costs and patient burden increase unnecessarily
Solution Approach 1:
The patent segments the DCIS population into distinct risk categories based on ion channel biomarkers. This segmentation allows resource allocation to be concentrated on high-risk patients who truly need aggressive treatment, while low-risk patients receive surveillance or less intensive management, thereby reducing overall treatment resource consumption without compromising cancer control.
Solution Approach 2:
The patent changes the diagnostic parameter from general DCIS diagnosis to specific ion channel expression profiling. By measuring biomarker levels (such as TRPV4, TRPA1, TRPM8, ATP1A1, and SCN9A), the patent transforms the treatment decision-making process into a parameter-based stratification system that optimizes resource utilization by treating only those patients whose biomarker profiles indicate high risk of progression.
3Measurement precision
If ion channel markers are used to identify high-risk DCIS, then treatment precision is improved, but diagnostic complexity increases
Solution Approach 1:
The patent employs universal immunohistochemical staining techniques that can detect multiple ion channel biomarkers simultaneously using standardized laboratory methods. This multi-functional approach allows the detection of various ion channel expressions (TRPV4, TRPA1, TRPM8, ATP1A1, SCN9A) through a single diagnostic platform, thereby maintaining measurement precision while avoiding the need for multiple separate complex tests.
Solution Approach 2:
The patent utilizes established immunohistochemical assays that are relatively simple, cost-effective, and widely available in routine pathology laboratories. These disposable staining protocols can be applied to existing tissue samples without requiring complex live-cell imaging equipment or sophisticated diagnostic devices, thereby reducing diagnostic complexity while maintaining high measurement precision for risk stratification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables more precise identification of high-risk DCIS cases, allowing for targeted treatment strategies that reserve aggressive interventions for those who need them, reducing unnecessary treatment and improving patient outcomes by distinguishing between low-risk and high-risk lesions.
Implementation Method 1
In some embodiments, the present disclosure provides methods and compositions that may be used to identify a breast tissue abnormality as a precursor to breast cancer in a subject in need thereof. In some embodiments, the present disclosure provides methods for treating breast cancer. Methods for treating breast cancer disclosed herein may comprise: i) identifying at least one precursor to breast cancer in a subject, wherein identification of the at least one precursor to breast cancer comprises collecting a tissue sample from a breast tissue abnormality in the subject, and identifying the at least one precursor to breast cancer in the subject as wherein one or more cells in the tissue sample has one or more ion channels localized at the plasma membrane
Data Source
AI summary
Embodiments of the instant disclosure relate to novel methods and compositions for distinguishing high-grade ductal carcinoma in situ (DCIS) from lower-grade DCIS in a breast tissue. Other embodiments of the instant disclosure provide for methods of administering one or more appropriate breast cancer treatment regimens to a subject diagnosed with high-risk DCIS.